{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:09:37Z","timestamp":1768295377565,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Optimal treatment with antiepileptic drugs (AEDs) is an important part of care for brain tumor patients with epileptic seizures. Lamotrigine and lacosamide are both examples of frequently used non-enzyme inducing AEDs with limited to no drug-drug interactions, reducing the risk of unfavorable side effects. This study aimed to compare the effectiveness of lamotrigine versus lacosamide.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this multicenter study we retrospectively analyzed data of patients with diffuse grade 2\u20134 glioma with epileptic seizures. All patients received either lamotrigine or lacosamide during the course of their disease after treatment failure of first-line monotherapy with levetiracetam or valproic acid. Primary outcome was the cumulative incidence of treatment failure, from initiation of lamotrigine or lacosamide, with death as competing event, for which a competing risk model was used. Secondary outcomes were uncontrolled seizures after AED initiation and level of toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included a total of 139 patients of whom 61 (44%) used lamotrigine and 78 (56%) used lacosamide. At 12\u00a0months, there was no statistically significant difference in the cumulative incidence of treatment failure for any reason between lamotrigine and lacosamide: 38% (95%CI 26\u201351%) versus 30% (95%CI 20\u201341%), respectively. The adjusted hazard ratio for treatment failure of lacosamide compared to lamotrigine was 0.84 (95%CI 0.46\u20131.56). The cumulative incidences of treatment failure due to uncontrolled seizures (18% versus 11%) and due to adverse events (17% versus 19%) did not differ significantly between lamotrigine and lacosamide.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Lamotrigine and lacosamide show similar effectiveness in diffuse glioma patients with epilepsy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-021-03800-z","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T09:03:20Z","timestamp":1625130200000},"page":"73-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide"],"prefix":"10.1007","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-4626","authenticated-orcid":false,"given":"Mark P.","family":"van Opijnen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pim B.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Dirven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Fiocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde C. M.","family":"Kouwenhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"van den Bent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J. B.","family":"Taphoorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan A. F.","family":"Koekkoek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"3800_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1515\/med-2019-0031","volume":"14","author":"J Wang","year":"2019","unstructured":"Wang J, Hu G, Quan X (2019) Analysis of the factors affecting the prognosis of glioma patients. Open Med 14:331\u2013335","journal-title":"Open Med"},{"issue":"4","key":"3800_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s12032-014-0911-x","volume":"31","author":"J Sun","year":"2014","unstructured":"Sun J, Shi H, Lai N, Liao K, Zhang S, Lu X (2014) Overexpression of microRNA-155 predicts poor prognosis in glioma patients. Med Oncol 31(4):911","journal-title":"Med Oncol"},{"issue":"6","key":"3800_CR3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.5858\/2008-132-906-TWCOTO","volume":"132","author":"GN Fuller","year":"2008","unstructured":"Fuller GN (2008) The WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med 132(6):906","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"3800_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.critrevonc.2006.06.007","volume":"60","author":"C Nieder","year":"2006","unstructured":"Nieder C, Adam M, Molls M, Grosu AL (2006) Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60(3):181\u2013193","journal-title":"Crit Rev Oncol Hematol"},{"key":"3800_CR5","doi-asserted-by":"publisher","first-page":"e539","DOI":"10.1016\/j.wneu.2017.12.112","volume":"111","author":"K Phan","year":"2018","unstructured":"Phan K, Ng W, Lu VM, McDonald KL, Fairhall J, Reddy R et al (2018) Association between IDH1 and IDH2 mutations and preoperative seizures in patients with low-grade versus high-grade glioma: a systematic review and meta-analysis. World Neurosurg 111:e539\u2013e545","journal-title":"World Neurosurg"},{"key":"3800_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/B978-0-12-802997-8.00016-5","volume":"134","author":"DJ Englot","year":"2016","unstructured":"Englot DJ, Chang EF, Vecht CJ (2016) Epilepsy and brain tumors. Handb Clin Neurol 134:267\u2013285","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"3800_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11060-018-2862-0","volume":"139","author":"DY Chen","year":"2018","unstructured":"Chen DY, Chen CC, Crawford JR, Wang SG (2018) Tumor-related epilepsy: epidemiology, pathogenesis and management. J Neurooncol 139(1):13\u201321","journal-title":"J Neurooncol"},{"issue":"42","key":"3800_CR8","doi-asserted-by":"publisher","first-page":"6464","DOI":"10.2174\/1381612823666171027130003","volume":"23","author":"C Vecht","year":"2017","unstructured":"Vecht C, Royer-Perron L, Houillier C, Huberfeld G (2017) Seizures and anticonvulsants in brain tumours: frequency, mechanisms and anti-epileptic management. Curr Pharm Des 23(42):6464\u20136487","journal-title":"Curr Pharm Des"},{"issue":"10","key":"3800_CR9","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s10072-019-04025-9","volume":"40","author":"M Maschio","year":"2019","unstructured":"Maschio M, Aguglia U, Avanzini G, Banfi P, Buttinelli C, Capovilla G et al (2019) Management of epilepsy in brain tumors. Neurol Sci 40(10):2217\u20132234","journal-title":"Neurol Sci"},{"issue":"2","key":"3800_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/neuonc\/nor205","volume":"14","author":"G You","year":"2012","unstructured":"You G, Sha ZY, Yan W, Zhang W, Wang YZ, Li SW et al (2012) Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro Oncol 14(2):230\u2013241","journal-title":"Neuro Oncol"},{"issue":"7","key":"3800_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1634\/theoncologist.2014-0060","volume":"19","author":"CJ Vecht","year":"2014","unstructured":"Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist 19(7):751\u2013759","journal-title":"Oncologist"},{"issue":"7","key":"3800_CR12","doi-asserted-by":"publisher","first-page":"e0180470","DOI":"10.1371\/journal.pone.0180470","volume":"12","author":"M Maschio","year":"2017","unstructured":"Maschio M, Beghi E, Casazza MML, Colicchio G, Costa C, Banfi P et al (2017) Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian epilepsy center. PLoS ONE 12(7):e0180470","journal-title":"PLoS ONE"},{"issue":"5","key":"3800_CR13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/epi.16880","volume":"62","author":"PB van der Meer","year":"2021","unstructured":"van der Meer PB, Dirven L, Fiocco M, Vos MJ, Kouwenhoven MCM, van den Bent MJ et al (2021) First-line antiepileptic drug treatment in glioma patients with epilepsy: levetiracetam vs valproic acid. Epilepsia. 62(5):1119\u20131129","journal-title":"Epilepsia."},{"issue":"3","key":"3800_CR14","first-page":"Cd001909","volume":"3","author":"M Panebianco","year":"2020","unstructured":"Panebianco M, Bresnahan R, Ramaratnam S, Marson AG (2020) Lamotrigine add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev 3(3):Cd001909","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3800_CR15","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.yebeh.2004.04.006","volume":"5","author":"TA Fakhoury","year":"2004","unstructured":"Fakhoury TA, Hammer AE, Vuong A, Messenheimer JA (2004) Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy. Epilepsy Behav 5(4):532\u2013538","journal-title":"Epilepsy Behav"},{"issue":"6","key":"3800_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.yebeh.2003.08.033","volume":"4","author":"L Kaminow","year":"2003","unstructured":"Kaminow L, Schimschock JR, Hammer AE, Vuong A (2003) Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy Behav 4(6):659\u2013666","journal-title":"Epilepsy Behav"},{"issue":"12","key":"3800_CR17","first-page":"Cd011412","volume":"12","author":"SJ Nevitt","year":"2017","unstructured":"Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG (2017) Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev 12(12):Cd011412","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"3800_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/epi.12074","volume":"54","author":"T Glauser","year":"2013","unstructured":"Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, K\u00e4lvi\u00e4inen R et al (2013) Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54(3):551\u2013563","journal-title":"Epilepsia"},{"issue":"1","key":"3800_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11060-017-2628-0","volume":"136","author":"R Rud\u00e0","year":"2018","unstructured":"Rud\u00e0 R, Pellerino A, Franchino F, Bertolotti C, Bruno F, Mo F et al (2018) Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. J Neurooncol 136(1):105\u2013114","journal-title":"J Neurooncol"},{"key":"3800_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.yebeh.2017.05.031","volume":"73","author":"M Maschio","year":"2017","unstructured":"Maschio M, Zarabla A, Maialetti A, Fabi A, Vidiri A, Villani V et al (2017) Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: a prospective explorative study with a historical control group. Epilepsy Behav 73:83\u201389","journal-title":"Epilepsy Behav"},{"issue":"4","key":"3800_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/epi.16486","volume":"61","author":"R Rud\u00e0","year":"2020","unstructured":"Rud\u00e0 R, Houillier C, Maschio M, Reijneveld JC, Hellot S, De Backer M et al (2020) Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES). Epilepsia 61(4):647\u2013656","journal-title":"Epilepsia"},{"issue":"7","key":"3800_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","volume":"47","author":"T Glauser","year":"2006","unstructured":"Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C et al (2006) ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47(7):1094\u20131120","journal-title":"Epilepsia"},{"issue":"2","key":"3800_CR23","doi-asserted-by":"publisher","first-page":"Cns53","DOI":"10.2217\/cns-2020-0009","volume":"9","author":"PB van der Meer","year":"2020","unstructured":"van der Meer PB, Dirven L, Fiocco M, Taphoorn MJ, Koekkoek JA (2020) Retention rates of antiepileptic drugs in glioma patients: the most appropriate outcome. CNS Oncol 9(2):Cns53","journal-title":"CNS Oncol"},{"key":"3800_CR24","unstructured":"UdoHaH. S Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [online] 2017 [Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs-\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 21 Aug 2020"},{"key":"3800_CR25","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index 2021., from: http:\/\/www.whocc.no\/atcddd\/. Accessed 19 Apr 2021"},{"issue":"11","key":"3800_CR26","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26(11):2389\u20132430","journal-title":"Stat Med"},{"key":"3800_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141\u20131154","journal-title":"Ann Stat"},{"issue":"6","key":"3800_CR28","first-page":"Cd001031","volume":"6","author":"SJ Nevitt","year":"2018","unstructured":"Nevitt SJ, Tudur Smith C, Weston J, Marson AG (2018) Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev 6(6):Cd001031","journal-title":"Cochrane Database Syst Rev"},{"issue":"9566","key":"3800_CR29","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW et al (2007) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369(9566):1000\u20131015","journal-title":"Lancet"},{"issue":"6","key":"3800_CR30","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3171\/2013.1.JNS12397","volume":"118","author":"MG Saria","year":"2013","unstructured":"Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM et al (2013) Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg 118(6):1183\u20131187","journal-title":"J Neurosurg"},{"issue":"11","key":"3800_CR31","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1007\/s00415-011-6132-8","volume":"258","author":"M Maschio","year":"2011","unstructured":"Maschio M, Dinapoli L, Mingoia M, Sperati F, Pace A, Pompili A et al (2011) Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol 258(11):2100\u20132104","journal-title":"J Neurol"},{"key":"3800_CR32","doi-asserted-by":"publisher","first-page":"107966","DOI":"10.1016\/j.neuropharm.2020.107966","volume":"168","author":"GJ Sills","year":"2020","unstructured":"Sills GJ, Rogawski MA (2020) Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 168:107966","journal-title":"Neuropharmacology."},{"issue":"4","key":"3800_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1212\/WNL.55.4.588","volume":"55","author":"AM Kanner","year":"2000","unstructured":"Kanner AM, Frey M (2000) Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 55(4):588\u2013591","journal-title":"Neurology"},{"issue":"6","key":"3800_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11940-015-0351-8","volume":"17","author":"R Rud\u00e0","year":"2015","unstructured":"Rud\u00e0 R, Soffietti R (2015) What is new in the management of epilepsy in gliomas? Curr Treat Options Neurol 17(6):351","journal-title":"Curr Treat Options Neurol"},{"issue":"10","key":"3800_CR35","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1136\/jnnp-2020-323524","volume":"91","author":"DG Vossler","year":"2020","unstructured":"Vossler DG, Knake S, O\u2019Brien TJ, Watanabe M, Brock M, Steiniger-Brach B et al (2020) Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry 91(10):1067\u20131075","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3800_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.yebeh.2016.02.041","volume":"58","author":"BJ Steinhoff","year":"2016","unstructured":"Steinhoff BJ, Eckhardt K, Doty P, De Backer M, Brunnert M, Schulze-Bonhage A (2016) A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures. Epilepsy Behav 58:35\u201343","journal-title":"Epilepsy Behav"},{"key":"3800_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2014.11.007","volume":"25","author":"V Paquette","year":"2015","unstructured":"Paquette V, Culley C, Greanya ED, Ensom MH (2015) Lacosamide as adjunctive therapy in refractory epilepsy in adults: a systematic review. Seizure 25:1\u201317","journal-title":"Seizure"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03800-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03800-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03800-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T09:09:59Z","timestamp":1629104999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03800-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["3800"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03800-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"12 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors declare a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}